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Abstract: In this work a hydrophilic interaction liquid chromatography/positive ion electrospray
mass spectrometric assay (HILIC/ESI-MS) has been developed and fully validated for the quantitation
of metformin and rosuvastatin in human plasma. Sample preparation involved the use of 100 µL
of human plasma, following protein precipitation and filtration. Metformin, rosuvastatin and
4-[2-(propylamino) ethyl] indoline 2 one hydrochloride (internal standard) were separated by using
an X-Bridge-HILIC BEH analytical column (150.0 × 2.1 mm i.d., particle size 3.5 µm) with isocratic
elution. A mobile phase consisting of 12% (v/v) 15 mM ammonium formate water solution in
acetonitrile was used for the separation and pumped at a flow rate of 0.25 mL min−1. The linear
range of the assay was 100 to 5000 ng mL−1 and 2 to 100 ng mL−1 for metformin and rosuvastatin,
respectively. The current HILIC-ESI/MS method allows for the accurate and precise quantitation
of metformin and rosuvastatin in human plasma with a simple sample preparation and a short
a chromatographic run time (less than 15 min). Plasma samples from eight patients were further
analysed proving the capability of the proposed method to support a wide range of clinical studies.
Keywords: rosuvastatin; metformin; HILIC; LC-MS; therapeutic drug monitoring
1. Introduction
Diabetes mellitus is a metabolic disorder caused by failures in the action and/or secretion of
insulin. During the last decades, incidents of diabetes have increased from 108 million to 422 million
corresponding mainly in type 2 diabetes mellitus [1]. Diabetes mellitus is a risk factor for a wide
range of vascular diseases like ischaemic stroke and coronary heart disease [2]. Metformin belongs
to a class of biguanides and it is usually administered for non-insulin-dependent type II diabetes
mellitus as the first line of treatment when lifestyle modification alone is not enough [3]. Several
studies in the literature report the beneficial protective effects of metformin administration in cardiac
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function, resulting in the deterioration of mortality caused from cardiovascular deceases as a result
of type 2 diabetes mellitus [4]. For the treatment of patients with type 2 diabetes mellitus it is often
required drug therapy with beneficial effects on the lowering of blood glucose and on dyslipidemia.
Statins are administered for the prevention of cardiovascular diseases and are also effective to prevent
vascular events in diabetic patients [5]. Rosuvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitor that is administered for hypercholesterolemia in patients with a high
risk of developing atherosclerosis and in patients with established cardiovascular disease [6].
Metformin and rosuvastatin are frequently prescribed in combination due to the high comorbidity
of these two diseases [7]. The development of novel analytical methods for therapeutic drug monitoring
is crucial to support the model of personalized medicine and the introduction of new drug combinations
in therapy. Thus, the purpose of this study was on the development of a new method to detect and
quantify those two commonly prescribed drugs in human plasma.
Several methods have been reported in literature for the quantitation of metformin alone [8–12]
or in combination with other drugs [13–21] in biofluids. A number of other methods have also
been reported in literature [22] for the quantitation of rosuvastatin alone [23–30] or in combination
with other drugs [31,32] in human plasma. The pharmacokinetic parameters of metformin and
rosuvastatin in healthy volunteers have been studied by the use of two different reversed-phase liquid
chromatography tandem mass spectrometric methods procedures for each analyte and complicated
sample preparation procedures involving liquid-liquid extraction [7]. A study on the pharmacokinetics
of rosuvastatin after concomitant administration of metformin and/or furosemide was conducted
by using two different RP-LC tandem mass spectrometric methods. The first method was used in
combination with a solid phase extraction procedure for the determination of metformin alone and
the second one in combination with a liquid-liquid extraction for the determination of rosuvastatin
and furosemide combination [33]. Recently, a reversed-phase tandem mass spectrometric method was
developed and fully validated for the simultaneous determination of metformin and rosuvastatin in
human plasma in combination with a simple sample preparation procedure [34]. Most recently a HILIC
method coupled to diode array detection has been published by our group for the quantitation of
rosuvastatin and metformin impurities in fixed-dose combination tablets containing rosuvastatin and
metformin [35]. To the extent of our knowledge, no bioanalytical assay has been previously developed
for the simultaneous quantitation of metformin and rosuvastatin in human plasma by hydrophilic
interaction liquid chromatography (HILIC) and by using a single quadrupole mass spectrometer.
HILIC offers improved sensitivity when combined with mass spectrometric detection due to the
high percentage of organic solvents used in the mobile phase in order to elute polar compounds.
The proposed method is suitable for therapeutic drug monitoring of metformin and rosuvastatin and
it has been successfully applied to the analysis of clinical samples obtained from patients that have
been treated with the analysed drugs.
2. Results and Discussion
2.1. Method Development
2.1.1. MS Detection Optimization
The parameters for electrospray ionization (ESI) have been optimized so as to allow maximum
abundance of the molecular ions of metformin, rosuvastatin and the ISTD. The mass spectrometer
was operated in positive ESI ion mode and selected ion monitoring (SIM) was used to analyze the
protonated molecules [M + H]+ at m/z 130, 482 and 219 for rosuvastatin, metformin and N-despropyl
ropinirole (ISTD), respectively. The maximum abundance of the selected ions was achieved when
capillary voltage, mass span and dwell time were set at 4.8 kV, 0.1 and 0.3 s, respectively. Mass spectra
of metformin, rosuvastatin and N-despropyl ropinirole (ISTD) are presented in Figure 1.
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Figure 1. ESI mass spectra in positive ion mode of a 10 µg mL−1 solution prepared in mobile phase of
(a) metformin (b) rosuvastatin and (c) N-despropyl ropinirole.
2.1.2. Chromatography
The chromatographic separation of compounds with a broad band of polarity can be easily
achieved by using HILIC chromatography [36]. The separation mechanism in HILIC combines
partition, reversed-phase interactions, normal phase/adsorption, electrostatic interactions and
hydrogen bonding and thus it is ideal to separate compounds with diverse physicochemical
properties [37]. Since metformin and rosuvastatin have sufficiently different physicochemical
properties a zwitterionic ZIC®-pHILIC analytical column has been used in preliminary experiments to
separate these compounds. In most of the mobile phases that have been tested rosuvastatin was eluted
very close to the solvent front even when the aqueous content of the mobile phase was reduced below
6%. Thus, a hydrophilic XBridge®-HILIC BEH analytical column was chosen in this work as the most
suitable for the chromatography. The packing material of this column consists of two kind of monomers,
bis-triethoxysilylethane and tetraethoxysilane, which are joined with ethylene bridges. Some accessible
silanols that remain on the surface of these BEH particles are responsible for electrostatic interactions.
Metformin is 100% positively-charged over a pH range from 1 to 12, while rosuvastatin is 100%
negatively-charged at pH values above 6. The internal standard, N-despropyl ropinirol is 100%
positively-charged over a pH range from 1 to 7.5. Previous findings, of our research group [35],
pointed out that the mechanism of separation for rosuvastatin and metformin in HILIC comprises both
secondary electrostatic interactions and hydrophilic partition.
Several combinations of the mobile phase constituents, acetonitrile asorganic modifier and
aqueous ammonium formate buffer, have been tested to optimize the chromatographic parameters
in order to achieve adequate separation of the analytes from matrix interferences and reach the best
sensitivity in ESI-MS detection. With a constant water content of the mobile phase eluent at 12%,
the concentration of the aqueous ammonium formate buffer was varied from 2.5 to 25 mM. Figure 2a
shows that the retention of both metformin and N-despropyl ropinirol is decreased by increasing the
concentration of ammonium formate up to 25 mM, while the retention of rosuvastatin is increased.
Based on the above findings it can be concluded for metformin and ISTD, that by increasing the
buffering salt concentration the electrostatic attraction between the positively-charged compounds
and the negatively-charged silanol groups of the XBridge®-HILIC BEH particle is reduced. On the
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contrary, for rosuvastatin the slight increase in retention by increasing the buffering salt concentration
reduces the electrostatic repulsion of the negatively charged rosuvastatin molecule and the negatively
charged silanol groups of the XBridge®-HILIC BEH particles. These results have been obtained
from the analysis of human plasma samples spiked with 2500 ng mL−1 metformin, 50 ng mL−1
rosuvastatin and 190 ng mL−1 of N-despropyl ropinirol (ISTD). It was also observed that by reducing
the concentration of ammonium formate below 10 mM the peak shape of metformin and N-despropyl
ropinirole was distorted and split. Thus, a 15 mM aqueous ammonium formate concentration was
chosen as the optimum.
Figure 2. Plots of logk values for rosuvastatin, metformin and N-despropyl ropinirole versus (a) the
concentration of ammonium formate, and (b) the percentage of the water of the mobile phase on an
XBridge®-HILIC BEH analytical column. Data have been obtained from the analysis of human plasma
samples spiked with 2500 ng mL−1 metformin, 50 ng mL−1 rosuvastatin and 190 ng mL−1 N-despropyl
ropinioro (ISTD).
The effect of the percentage of water, φwater, was also evaluated in experiments where φwater
was varied from 7 to 16% while the concentration of ammonium formate was kept constant at the
optimum value of 1.8 mM (pH = 6.5) in whole mobile phase. As it can be observed in Figure 2b,
the retention of the analytes decreases linearly with increasing the percentage of water, implying a
partition mechanism in HILIC separation. It was also observed an improvement in ESI/MS sensitivity
for metformin (Figure 3a) and rosuvastatin (Figure 3b) by decreasing the concentration of the buffering
salt in the mobile phase, while the percentage of water, φwater, was kept constant at 12% (v/v).
Figure 3. Impact of the concentration of ammonium formate in the mobile phase on the MS signal
of (a) metformin and (b) rosuvastatin. Data have been obtained from the analysis of human plasma
samples spiked with 2500 ng mL−1 metformin, 50 ng mL−1 rosuvastatin and 190 ng mL−1 N-despropyl
ropinioro (ISTD).
Based on the above studies, the optimum mobile phase composition consists of 12% 15 mM
ammonium formate water solution pH 6.5 in acetonitrile. The proposed HILIC-ESI/MS method
allows the isocratic separation of the analytes with 15 min. After column equilibration time of 1 h a
great number of samples can be analysed within one analytical daily batch. The internal standard,
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N-despropyl ropinirol, exhibits adequate ion intensity and good chromatographic peak shape under
the selected chromatographic and MS conditions. This compound is an impurity of ropinirol, thus,
it cannot be found in human plasma of patients.
The selectivity of the proposed method is illustrated in Figure 4, where a representative ion
chromatogram of a blank plasma sample is overlaid with ion chromatograms of calibration plasma
samples spiked with 100 and 1000 ng mL−1 of metformin and 2 and 20 ng mL−1 of rosuvastatin,
respectively and 190 ng mL−1 of N-despropyl ropinirol (ISTD). Rosuvastatin, metformin and
N-despropyl ropinirol were eluted at 2.4, 7.7 and 6.3 min, respectively.
Figure 4. Ion chromatogram (SIM mode) of a blank human plasma sample (black line) overlaid with
ion chromatograms (SIM mode) of calibration spiked plasma samples at 2 ng mL−1 (solid line) and
20 ng mL−1 (dashed line) of rosuvastatin (blue line), 100 ng mL−1 (solid line) and 1000 ng mL−1
(dashed line) of metformin (red line) and 190 ng mL−1 of ISTD (green line).
2.1.3. Optimization of the Preparation of the Biological Sample
Protein precipitation is a simple sample preparation procedure that allows for the analysis of a
large number of samples in short time. In this work protein precipitation gave adequate recovery for
metformin, rosuvastatin and the ISTD, while further filtration was applied to minimize the matrix
interference, and to prolong the column life time and prevent system blockages [38]. In HILIC the
nature of the dissolution solvent is more crucial than in reversed-phase HPLC on the chromatographic
peak shape. It was observed during method development that the peak shapes of metformin and
rosuvastatin were split and distorted in different dissolution solvent mixtures and by changing the
percentage of the biological sample in the injection sample.
Various proportions of human plasma have been tested to determine the optimum amount of
biological material for the analyses. Figure 5 shows that by increasing the amount of human plasma
up to 100 µL, peak area signal of metformin (Figure 5a) and rosuvastatin (Figure 5b) was increased.
A further increase of human plasma above 100 µL caused serious distortion of the peak shapes
of the analytes. Thus, analysis was performed by using 100 µL of biological sample. To further
improve the chromatographic peak shapes, buffered eluents have been used. Therefore, we tested
different concentrations of 30% (v/v) ammonium formate water solution in the dissolution solvent.
Results presented in Figure 5c,d, for metformin and rosuvastatin, respectively, indicate that peak area
signal of rosuvastatin decreases by increasing the concentration of ammonium formate. We concluded
that the best peak shapes were obtained by using 100 µL of biological sample and processed with a
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dissolution solvent mixture consisting of 30% (v/v) of an ammonium formate water solution at 5 mM
(pH 6.5) in acetonitrile. A membrane syringe filter was also used for the filtration of the samples prior
to HILIC-ESI/MS analysis. Filtration was essential to remove any additional matrix interferences
and increase the sensitivity in HILIC-ESI/MS system. To evaluate whether filtering of the processed
biological samples would cause loss of the analytes, eight different types of syringe filters were selected
for testing, five 0.45 µm pore size and three 0.22 µm pore size, all 13 mm diameter.
Figure 5. Effect of the proportion of the biological sample (a and b) and the concentration of a 30%
(v/v) ammonium formate water solution in acetonitrile (c and d) on the peak area signal of metformin
and (b,d) rosuvastatin.
To evaluate the % recovery, the peak area of spiked plasma samples was compared with the
analytical response of blank plasma samples spiked with the equivalent concentration of the analytes
after the sample preparation and filtration procedure. Data presented in Figure 6, shows the % recovery
of the analytes under the various types of the filters that have been tested.
Figure 6. Effect of the type of the filters used for sample preparation of the biological samples on the %
recovery of the analytes.
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Optimum % recovery for metformin and rosuvastatin was achieved when a 100 µL aliquot of
each human plasma sample was processed by the addition of 50 µL of ISTD solution (3.8 µg mL−1),
30 µL of 5 mM ammonium formate solution in water and 820 µL of acetonitrile. After vortex mixing
and centrifugation, the supernatant was filtered through a 13 mm PTFE membrane syringe filter
(hydrophilic) with a pore size of 0.45 µm.
2.2. Statistical Analysis of Data
2.2.1. Selectivity and Specificity
The selectivity test met the pre-defined criteria as co-eluting peaks where less than 5% of the area
of metformin and rosuvastatin at the LOQ level, and less than 5% of the area of N-despropyl ropinirole
in the ion chromatograms (SIM mode) obtained from the analysis of six batches of human plasma.
The carry-over test has been performed by analysing blank human plasma samples after the injection
of the highest concentration calibration and showed no interfering peaks with peak areas greater than
5% of the peak areas at the LOQ level of metformin and rosuvastatin.
2.2.2. Linearity, Precision and Accuracy
A weighting factor of 1/y2 was used for the linear regression analysis and data presented in
Table 1, indicate that linear relationships have been achieved between the measured signal ratios of
the analytes and the corresponding concentrations. In agreement with international guidelines [39],
the back-calculated concentrations in the calibration curves were less than 11.5% and 14.5% of the
nominal concentration of metformin and rosuvastatin.
Table 1. Analytical concentration parameters of the calibration equations for the determination of
metformin and rosuvastatin in human plasma by HILIC-ESI/MS.
Compound Concentration
Range, ng mL−1 Regression Equations
a r b
Standard Deviation
Sr c
Slope Intercept
Mean of three calibration curves over a period of one month
Metformin 62.5–5000 RMtf = 0.00715 × CMtf + 0.066 ≥0.996 2.2 × 10−4 4.3 × 10−4 ≤0.10
Rosuvastatin 2–100 RRsv = 0.01775 × CRsv − 0.0129 ≥0.998 5.2 × 10−4 7.2 × 10−3 ≤0.062
a Ratios of the peak areas signals of metformin, RMtf and rosuvastatin, RRsv, to that to the internal standard vs. the
corresponding concentration of metformin, CMtf and rosuvastatin, CRsv; b Correlation coefficient; c Standard error
of the estimate.
The LOD and LLOQ were estimated from the signal-to-noise ratio (S/N) and by analysing
human plasma samples spiked with metformin and rosuvastatin at low concentrations. The LOD was
estimated at a S/N ratio of 3:1 and the LLOQ was estimated at a S/N ratio of at least 10:1, until a % CV
of less than 20% was obtained. The LODs were found to be at 11 and 0.3 ng mL−1, and the LLOQs at
35 and 1 ng mL−1, for metformin and rosuvastatin, respectively.
Precision and accuracy data are presented in Table 2 and indicate that intra-assay coefficients
of variations, % CV, were between 5.3% and 9.1% for metformin and between 6.2% and 8.5% for
rosuvastatin. The inter-assay % CVs were lower than 3.0% and 7.1% for metformin and rosuvastatin,
respectively. The overall accuracy, which was assessed by the percentage relative error, was ranged
from −3.3 to 0.4% for metformin and from −1.1 to 7.0% for rosuvastatin.
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Table 2. Data on accuracy and precision obtained from the analysis of quality control samples
containing rosuvastatin and metformin (n = 3 runs; five replicates per run).
Compound Concentration (ng mL−1)
Metformin
Added Concentration 62.5 500 5000
Run 1 (mean ± s.d.) 63.9 ± 6.1 489 ± 29 5045 ± 352
Run 2 (mean ± s.d.) 64.3 ± 5.1 42.9 ± 8.3 4698 ± 143
Run 3 (mean ± s.d.) 60.1 ± 6.0 488 ± 39 4768 ± 232
Overall mean 62.7 497.9 4837
Intra-day CV (%) a 9.1 7.6 5.3
Inter-day CV (%) a 1.8 1.0 3.0
Overall accuracy Er% b 0.4 −0.4 −3.3
Rosuvastatin
Added Concentration 2 10 100
Run 1 (mean ± s.d.) 2.31 ± 0.21 9.41 ± 0.33 104.1 ± 6.6
Run 2 (mean ± s.d.) 2.12 ± 0.22 9.61 ± 0.89 96.5 ± 5.7
Run 3 (mean ± s.d.) 2.01 ± 0.21 10.81 ± 0.46 96.2 ± 9.1
Overall mean 2.1 9.9 98.9
Intra-day CV (%) a 8.5 6.2 7.3
Inter-day CV (%) a 4.4 7.1 3.0
Overall accuracy Er% b 7.0 −1.0 −1.1
a Intra- and inter-assay coefficient of variations as calculated by ANOVA. b Relative percentage error.
2.2.3. Recovery and Matrix Effect
Recovery data are presented in Table 3 and indicate average recovery of more than 92.6% and
95.8% for metformin and rosuvastatin, respectively. The average recovery for N-despropyl ropinirol
(ISTD) was found to be 91.7 ± 3.8%.
Table 3. Recovery and ion suppression data for the quantitation of metformin and rosuvastatin by
HILIC-ESI/MS.
Compound Concentration Levels (ng mL−1)
Metformin 1000 5000
% Recovery (mean ± s.d.)n = 3 92.6 ± 2.5 93.9 ± 1.4
% Matrix Factor (mean ± s.d.)n = 3 59.9 ± 1.0 63.7 ± 1.3
Rosuvastatin 20 100
% Recovery (mean ± s.d.)n = 3 96.6 ± 2.1 95.8 ± 4.1
% Matrix Factor (mean ± s.d.)n = 3 84.5 ± 7.1 81.3 ± 2.0
N-despropyl ropinirole (ISTD) 3800
% Recovery (mean ± s.d.)n = 3 91.7 ± 3.8
% Matrix Factor (mean ± s.d.)n = 3 61.8 ± 1.8
The method described by Matuszewski et al. [40] was used to evaluate the matrix effect for
metfromin, rosuvastatin and the ISTD. The matrix effect was expressed by the percentage matrix factor
which is defined as the percentage of the ratio of the analyte peak response in the presence of matrix
ions to the analyte peak response in the absence of matrix ions. As shown by the results presented
in Table 4, the % matrix factor was greater than 59.9% and 81.3% for metformin and rosuvastatin,
respectively indicating low ion suppression. The % matrix factor for N-despropyl ropinirol (ISTD) was
found to be 61.8 ± 1.8%.
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Table 4. Stability data for metformin and rosuvastatin in human plasma under various
storage conditions.
Compound Calculated Concentration (ng mL−1)
Metformin 50 1250 2500
Mean ± S.D.(n = 3) %Er a Mean ± S.D.(n = 3) %Er a Mean ± S.D.(n = 3) %Er a
Ambient temperature/4 h 50.4 ± 1.9 0.9 1271.5 ± 8.2 1.7 2522 ± 138 0.01
−20 ◦C/4 weeks 49.7 ± 2.1 −0.6 1260.1 ± 0.80 0.8 2412 ± 18 −0.04
−20 ◦C/4 Freeze-thaw cycles 51.21 ± 0.81 2.4 1282.3 ± 2.6 2.6 2386 ± 24 −0.05
Rosuvastatin 2.5 25 50
Ambient temperature/4 h 2.509 ± 0.0089 0.4 24.72 ± 0.11 −1.1 49.4 ± 3.4 −0.9
−20 ◦C/4 weeks 2.457 ± 0.045 −1.7 24.53 ± 0.15 −1.9 50.2 ± 3.2 0.4
−20 ◦C/4 Freeze-thaw cycles 2.435 ± 0.031 −2.6 24.94 ± 0.42 −0.2 49.5 ± 2.4 −1.0
a %Er: relative percentage error = (overall mean assayed concentration − added concentration)/(added
concentration) × 100.
2.2.4. Stability
The stability of the analytes in spiked human plasma samples was evaluated under various
storage conditions presented in detail in Table 4. To evaluate stability the results of the stored samples
were compared to the results of the freshly prepared samples spiked with the analytes in human
plasma at equivalent concentrations.
Stability results are presented in Table 4 and indicate that the concentrations of metformin and
rosuvastatin deviate by no more than −2.6% relative to the reference for any of the analytes. Thus,
human plasma samples containing metformin and rosuvastatin may be kept without any substantial
degradation under the various tested storage conditions.
2.3. Application to the Analysis of Real Samples
Human plasma samples collected from patients that were treated with the analytes have been
analysed by the current method so as to demonstrate the applicability of the method to support several
clinical studies related to metformin and rosuvastatin therapy. Human plasma samples collection
was approved by the local Ethics Committee of clinical settings, although not demanded by national
legislation, as this study is not regarded as a clinical trial.Blood samples were collected in tubes
containing sodium heparin as anticoagulant and immediately after drawing, the samples were shaken
gently and centrifuged at 4000 rpm for 10 min at 4 ◦C. Human plasma samples were stored at −20 ◦C
and analysed within two weeks after storage by the proposed HILIC-ESI/MS method. In particular,
plasma samples obtained from eight human patients (five female and three male) with ages ranging
from 57 to 88 years old have been analysed by the proposed method. During the period of sample
collection, all of the patients had receiving other medication described in detail in Table 5.
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Table 5. Clinical data in patients treated with rosuvastatin and metformin.
Patient
Sex/Age
(years)
Time Post
Dose (h)
Drug/Dose
Peros (mg)
C (ng mL−1)
Mean ±
S.D.(n = 3)
Co-Administered Drugs
♀/57 21/2
Metformin/1000
× 1 × 30 days
Rosuvastatin/10
× 1 × 30 days
1956 ± 93
22.2 ± 0.4 Acetylsalicylic acid 100 mg tb 1 × 1
♂/64 11 Rosuvastatin/20× 1 × 30 days 16.2 ± 1.4 Furosemide 40 mg tb 1 × 1, ramipril 2.5 mg tb 1 × 1,carvedilol 6.35 mg tb 1 × 1.
♂/63 16 Rosuvastatin/20× 1 × 30 days 9.21 ± 0.39
Nadroparin 5700 anti-ha 1 × 1 subcutaneous, omeprazole
caps 20 mg 1 × 1, metoprolol tb 25 mg 1 × 2, sulbactam 1 g &
ampicillin i.v. 1 × 3 × 5 days, acetyl salicylic acid 100 mg
E.C.tb 1 × 1, atalopram 20 mg 1 × 1.
♀/80 21/2 Metformin/1000× 1 × 30 days 2635 ± 67
Acetylsalicylic acid 100 mg tb 1 × 1, insuline glarine 100
iu/mL 10IU ×1 night subcutaneous, Ramipril 5 mg tb 1 × 1,
nadropanin 2850 Anti-xa 1 × 1, piracetam i.v. 1 × 2.
♀/83 10 Metformin/1000× 2 × 30 days 1850 ± 55
Furosemide 20 mg tb 1 × 1, 1 × 1, insuline glarine 100 iu/mL
14IU ×1 night subcutaneous, pantoprazole 40 mg caps 1 × 1,
T4-50 1 × 1, carvedilol 12.5 mg tb 1 × 2, apixaban 2.5 mg tb 1
× 2, Lutein/Zeaxanthine/Mesozeaxanthine caps 1 × 1,
VITAMIN D3 2000 IU 1 × 1.
♂/70 21/2 Metformin/850× 2 × 30 days 1856 ± 84
Ezetimibe/simvastatin 10/40 mg tb 1 × 1, gliclazide 30 mg tb
1 × 1, sertraline 50 mg tb 1 × 2, galantamine 8 mg caps 1 × 1,
levodopa/carvidopa/entacapone 100/25/200 tb 1 × 3,
clopidogrel 75 mg tb 1 × 1.
♀/88 12 Metformin/850× 1 × 30 days 1676 ± 60
Atorvastatin tb 40 mg 1 × 1, furosemide 20 mg i.v. 2 × 3,
bisoprostol 10 mg 1 × 1, insuline glarine 100 iu/mL 10IU ×1
night subcutaneous, thyrormone 100 mg 1 × 1, acetyl salicylic
acid 100 mg E.C.tb 1 × 1, digoxin tb 0.25 mg 12 × 1.
♀/88 16 Metformin/850× 1 × 30 days 226 ± 12
Atorvastatin tb 40 mg 1 × 1, furosemide 20 mg i.v. 2 × 3,
insuline glarine 100 iu/mL 10IU ×1 night subcutaneous,
thyrormone 100 mg 1 × 1, digoxin tb 0.25 mg 12 × 1, acetyl
salicylic acid 100 mg E.C. tb 1 × 1.
As shown by the clinical data presented in Table 5, rosuvastatin was quantitated in human plasma
samples obtained from two male patients who had receiving 20 mg of rosuvastatin once daily in the
morning (Crestor® 20, AstraZeneca A.E., Cambridge, UK) for a long-term treatment and blood samples
were collected at 11 and 16 h after dosing. The concentrations of rosuvastatin ranged from 9.21 ± 0.39
to 16.2 ± 1.4 ng mL−1.
Metformin was quantitated in human plasma samples obtained from five patients (four female
and one male) who had receiving either 1000 mg of metformin (Glucophage® 1000, Merck A.E.,
Kenilworth, NJ, USA) once daily in the morning or 850 mg of metformin twice daily (Glucophage®
850, Merck A.E.) and for a long-term treatment. The concentrations of metformin ranged from
226 ± 12 to 2635 ± 67 ng mL−1.
Rosuvastatin and metformin were quantitated in one female patient who had receiving 1000 mg of
metformin once daily (Glucophage® 1000, Merck A.E.) and 10 mg of rosuvastatin once daily (Crestor®
10, AstraZeneca A.E.). Plasma sample obtained from this patient exhibited metformin and rosuvastatin
plasma concentrations 1956 ± 93 ng mL−1 and 22.2 ± 0.4 ng mL−1, respectively.
3. Materials and Methods
3.1. Chemicals and Reagents
Metformin hydrochloride of pharmaceutical purity grade was purchased from Wanbury Limited
(BSEL Tech Park, Maharashtra, India). Rosuvastatin calcium of pharmaceutical purity grade was
obtained from MSN Laboratories Private Limited (Rudraram, Telengana, India). The internal standard,
N-despropyl ropinirole was purchased from Vitalife Chemipharma Pvt. Ltd. (Mumbai, Maharashtra,
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India). HPLC grade solvents were used and purchased from E. Merck (Darmstadt, Germany).
A Synergy UV water purification system (Merck Millipore, Danvers, MA, USA) was used to provide
water HPLC grade. Hydrophilic polytetrafluorethylene membrane syringe filters (PTFE, 13 mm,
pore size 0.45 µm) were purchased from Merck Millipore (Danvers, MA, USA). Pooled drug-free
human plasma was obtained from National Red Cross General Hospital, Athens, Greece.
3.2. Instrumentation
A single quadrupole mass spectrometer model Finnigan AQA (Thermo, Manchester, UK)
equipped with an electrospray ionisation interface and an isocratic pump model Spectra Series
P100 (ThermoSeparation, Piscataway, NJ, USA) LC system were used to perform the HILIC-ESI/MS
experiments. Highly pure nitrogen was produced by using a Model Nitrox-N2, Domnick hunter
(Gateshead, UK) nitrogen generator. Xcalibur software (v. 1.2, ThermoQuest, Austin, UK) was used
for data acquisition and analysis. Metformin, rosuvastatin and N-despropyl ropinirol were separated
using a Xbridge HILIC BEH analytical column (150.0 × 2.1 mm i.d., particle size 3.5 µm, 135 Å).
To prolong column lifetime, a XBridge HILIC BEH guard cartridge (20 × 2.1 mm, 3.5 µm) was also
used. A mobile phase comprising of 12% 15 mM ammonium formate water solution in acetonitrile and
pumped at a flow rate of 0.25 mL min−1 was used to run the experiments. The mobile phase was always
filtered prior to use through a 0.45 µm nylon-membrane filter, GelmanSciences (Northampton, UK)
and degassed under vacuum. Chromatography was performed at 25 ± 2 ◦C with a chromatographic
run time of 15 min. All analytes and the ISTD have been detected in electrospray positive ionization
mode and quantitation was achieved in SIM mode. Source parameters were adjusted to the following
settings: temperature 260 ◦C, capillary voltage 4.8 kV, cone voltage 20 V.
3.3. Stock and Working Standard Solutions
Stock standard solutions of metformin and rosuvastatin were prepared at 500 µg mL−1 in
acetonitrile-water mixture (90:10, v/v). These stock standard solutions were diluted in acetonitrile
to prepare the mixed working standard solutions over the concentration ranges of 62.5 to 5000 ng
mL−1 and 2 to 100 ng mL−1 for metformin and rosuvastatin, respectively. Stock standard solution
of N-despropyl ropinirole (ISTD) was prepared at 190 µg mL−1 in acetonitrile. A working standard
solution of ISTD at 3.8 µg mL−1 was prepared after further dilution in acetonitrile. The stock standard
solutions were found to be stable for several months when stored at −20 ◦C. The working standard
solutions were stored at 4 ◦C and prepared every month.
3.4. Calibration Standards and Quality Control Samples
Calibration standards spiked in human plasma were prepared at seven different concentration
levels 62.5, 100, 250, 500, 1000, 2500 and 5000 ng mL−1 for metformin and at six different concentration
levels 2, 5, 10, 20, 50 and 100 ng mL−1 for rosuvastatin. Each calibration sample contained 190 ng mL−1
of the internal standard. Quality control (QC) samples were prepared independently, in an analogous
manner as the calibration standards, using separate stock solutions of the analytes. QC samples were
prepared at three different concentration levels (62.5, 500 and 5000 ng mL−1) for metformin and (2,
10 and 100 ng mL−1) for rosuvastatin in human plasma.
3.5. Sample Preparation Procedure
Cleanup of biological samples is carried out by protein precipitation. On the day of extraction
the samples are thawed at room temperature followed by vortex mixing to ensure homogeneity.
Consequently, a 100 µL aliquot of each human plasma sample is transferred to a 2 mL Eppendorf tube,
followed by addition of 50 µL of ISTD solution (3.8 µg mL−1), 30 µL of 5 mM ammonium formate
solution in water and 820 µL of acetonitrile. The mixture is vortexed for 1.0 min and centrifuged at
16,000× g for 20 min at 25 ◦C. A 13 mm hydrophilic PTFE membrane syringe filter (pore size 0.45 µm)
is then used to filter the samples prior to HILIC-ESI/MS analysis.
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4. Conclusions
In this work the advantages of HILIC, on the separation of compounds with diverse
physicochemical properties and on the improvement in ESI/MS sensitivity, were demonstrated through
the development of a HILIC-ESI/MS for the quantitation of metformin and rosuvastatin in human
plasma. For the first time metformin and rosuvastatin have been adequately retained and separated
from matrix interferences with an analytical run time of 15 min by using a hydrophilic Xbridge®-HILIC
BEH analytical column. The method is combined with a fast and simple procedure for sample
preparation based on protein precipitation and filtration that requires only 100 µL of biological sample.
Validation results demonstrate that under the optimum conditions metformin and rosuvastatin can be
quantified accurately and precisely in human plasma. The method was successfully applied to the
analysis of real samples and it can be used to support various clinical studies.
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